N/A N=129 JETi Lower Extremity Arterial Thrombosis
Arterial Thrombosis
Primary: Primary Effectiveness Endpoint - Clot Removal Grade From Pre-JETi to Post-JETi - Core Lab Assessed - Per Vessel Analysis — 36; 41; 52; 93 Vessels
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
N/A N=1,480 An International Pulmonary Embolism Registry Using EKOS
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Phase 4 N=131 Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
Phase 3 N=14 Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
N/A N=8,256 Epidemiology of Thromboembolism Disease: A Cohort Study
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
N/A N=122 Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
Pulmonary Embolism · Acute Pulmonary Embolism
Primary: Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA) — -0.45 ratio
Phase 3 N=5,395 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Phase 3 N=6,528 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
Venous Thrombosis · Pulmonary Embolism
Primary: Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population — 2.71…
N/A N=1,000 FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
Phase 4 N=49 Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
Primary Total Hip and Knee Arthroplasty
Primary: Blood Loss — 6; 1 participants
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
Phase 3 N=59 ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
Phase 4 N=103 Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
Traumatic Injury · Venous Thromboembolism
Primary: Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization — 87; 82 Percent AT-III activity (%) — p=0.092
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
N/A N=119 Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism
Pulmonary Embolism
Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio
N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
Phase 3 N=2,856 Secondary Prevention of Venous Thrombo Embolism (VTE).
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137